IFNG and melanoma: A DC-based vaccine in combination with anti-PD-L1 and anti-CTLA-4 showed the elimination of ALDHhigh CSCs, enhanced T-cell expansion, suppressed TGF-β secretion, enhanced IFN-γ secretion, and significantly enhanced host specific CD8+ T-cells against CSCs in mouse melanoma [96].